COVIran Barekat is the first vaccine developed in Iran that has been approved. It is about a vaccine of an inactivated virus developed by the pharmaceutical company Shifa Pharmed Industrial CO, which uses a dead version of the virus that causes the disease, unable to infect but able to trigger an immune response.
Preclinical studies of the drug candidate showed "adequate safety and efficacy" results, and invited to develop clinical trials in humans.
Phase I studies started in late 2020 with a sample of 56 volunteers, and were followed by phase II/III studies on a total of 20,000 people, according to the Iranian clinical trials registry. Official results of these trials have not yet been published, nor is there any statement assessing the efficacy of the injection.
Immunisation with COVIran Barekat consists of two doses separated by a 28-day period. No information on storage temperature has been published.
We are a team of young journalists from Barcelona who work independently to combat misinformation in our territory and beyond. We rely on facts and data to verify what politicians say and the falsehoods circulating on social media.
We need you. With your contribution, you will contribute to a healthier political debate and help promote educational projects to teach citizens how to navigate information chaos and defend themselves against misinformation.
You can contribute as much as one euro and it won't take you more than 45 seconds (we've counted them). If you can, please mark your contribution as monthly and so we can continue to do our job rigorously and independently. Thank you so much.
Donate